Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
By J. Bonner, P. Harari, J. Giralt, R. Cohen, Christopher U. Jones, R. Sur, D. Raben, J. Baselga, S. Spencer, Junming Zhu and 3 more. The Lancet Oncology, 2010
1,955 citations recorded by the source corpus.
Subfields: Otorhinolaryngology, Surgery
View Paper: https://www.semanticscholar.org/paper/49a04afdc7403372cc6575923c096902da291a95
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Otorhinolaryngology
Citations in the corpus
- Strategies to improve radiotherapy with targeted drugs (2011, background): “gov/drugdictionary/?CdrID=42384">cetuximab , in combination with radiotherapy, which significantly increased local-regional control and overall survival in a Phase III trial in head and neck cance”